#1 Clinical Trials Search in Europe

Tradipitant

Tradipitant is a promising drug currently being studied in several clinical trials for its potential to treat various medical conditions. These trials are investigating the safety and efficacy of Tradipitant in addressing symptoms related to gastroparesis, motion sickness, functional dyspepsia, and even COVID-19. Researchers are exploring how this medication might improve the quality of life for patients suffering from these conditions by targeting specific symptoms and evaluating its overall impact on patient health.

Table of Contents

What is Tradipitant?

Tradipitant is a medication currently being studied for its potential to treat various medical conditions. It is classified as an NK-1 receptor antagonist, which means it works by blocking a specific type of receptor in the body called neurokinin-1 (NK-1)[1]. This mechanism of action is believed to help alleviate symptoms in several disorders.

Conditions Treated with Tradipitant

Research is ongoing to evaluate the effectiveness of tradipitant in treating several conditions, including:

  • Motion sickness
  • Gastroparesis (both idiopathic and diabetic)
  • Functional dyspepsia
  • COVID-19 (severe cases)

Tradipitant for Motion Sickness

Several studies are investigating the use of tradipitant for motion sickness. These trials aim to determine if tradipitant can effectively prevent vomiting and other symptoms associated with motion sickness during travel[2][3].

In these studies, participants are given either tradipitant or a placebo before traveling. Researchers then measure the occurrence of vomiting and other motion sickness symptoms to evaluate the drug’s effectiveness.

Tradipitant for Gastroparesis

Gastroparesis is a condition where the stomach takes too long to empty its contents. It can be idiopathic (of unknown cause) or associated with diabetes. Tradipitant is being studied as a potential treatment for both types of gastroparesis[4].

In clinical trials, researchers are evaluating how tradipitant affects symptoms such as:

  • Nausea
  • Vomiting
  • Feeling full after eating only a small amount (early satiety)
  • Abdominal pain

Patients in these studies typically take tradipitant twice daily and report their symptoms using specialized questionnaires.

Tradipitant for Functional Dyspepsia

Functional dyspepsia is a disorder that causes discomfort or pain in the upper abdomen without a clear cause. A study is underway to see if tradipitant can help patients with this condition[5].

The research focuses on how tradipitant affects:

  • Gastric motor functions (how the stomach moves and processes food)
  • Satiation (feeling full)
  • Symptoms that occur after eating

Researchers use advanced imaging techniques like single photon emission computed tomography (SPECT) to measure changes in stomach function after taking tradipitant.

Tradipitant for COVID-19

During the COVID-19 pandemic, a study called ODYSSEY was conducted to investigate if tradipitant could help patients with severe COVID-19 infections[6]. The research aimed to determine if tradipitant could:

  • Reduce lung inflammation
  • Improve clinical outcomes
  • Decrease the viral load of COVID-19

This study highlights the potential versatility of tradipitant in treating different medical conditions.

Safety and Side Effects

As with any medication, researchers are carefully monitoring the safety and potential side effects of tradipitant. In clinical trials, safety is assessed through various methods, including[7]:

  • Reporting of adverse events
  • Monitoring vital signs
  • Blood tests
  • Electrocardiograms (ECGs)
  • Urine tests

It’s important to note that as tradipitant is still being studied, not all potential side effects may be known. Patients participating in clinical trials are closely monitored for any unexpected reactions.

Ongoing Research

Tradipitant is still in the research phase, with several clinical trials ongoing or planned. These studies aim to better understand how the drug works, its effectiveness for various conditions, and its long-term safety profile.

Some areas of ongoing research include:

  • Optimal dosing for different conditions
  • Long-term effects of tradipitant use
  • Potential interactions with other medications
  • Genetic factors that may influence treatment response

As research progresses, more information will become available about the potential benefits and risks of tradipitant. Patients interested in this medication should discuss it with their healthcare providers and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name Tradipitant
Drug Class Neurokinin-1 (NK-1) receptor antagonist
Administration Oral capsules, typically twice daily (BID)
Conditions Studied Gastroparesis (idiopathic and diabetic), Motion Sickness, Functional Dyspepsia, COVID-19, Obesity-related nausea/vomiting
Primary Outcomes Reduction in nausea severity, prevention of vomiting, changes in gastric motor functions, safety and tolerability
Secondary Outcomes Changes in other gastroparesis symptoms, global improvement measures, gastric accommodation, satiation, gastric emptying
Safety Monitoring Adverse events, vital signs, blood chemistry, hematology, ECGs, psychiatric assessments
Study Designs Randomized, double-blind, placebo-controlled trials; open-label safety studies

FAQ

  • What is Tradipitant and how does it work? Tradipitant is a neurokinin-1 (NK-1) receptor antagonist. It works by blocking the action of substance P, a neurotransmitter involved in various bodily functions, including nausea and vomiting. By inhibiting this receptor, Tradipitant may help alleviate symptoms associated with conditions like gastroparesis and motion sickness.
  • What medical conditions are being studied with Tradipitant? Clinical trials are investigating Tradipitant for several conditions, including idiopathic and diabetic gastroparesis, motion sickness, functional dyspepsia, and even severe COVID-19 infection. Some studies are also looking at its effects on gastric motor functions and satiation in healthy volunteers.
  • How is Tradipitant administered in these clinical trials? In most of the clinical trials, Tradipitant is administered orally in the form of capsules. The dosage and frequency vary depending on the study, but many trials use a twice-daily (BID) dosing schedule.
  • What are the primary outcomes being measured in Tradipitant trials? The primary outcomes vary depending on the condition being studied. For gastroparesis, researchers often measure changes in nausea severity. In motion sickness trials, prevention of vomiting is a key outcome. Other studies look at gastric motor functions, safety profiles, and changes in specific symptom scores related to the condition being treated.
  • Are there any known side effects of Tradipitant? While specific side effects are not detailed in the provided trial information, all studies include safety monitoring as a key component. This typically involves tracking adverse events, vital signs, blood chemistry, hematology, and ECG measurements. Some trials also use specific tools like the Columbia-Suicide Severity Rating Scale (C-SSRS) to monitor for potential psychiatric side effects.

Ongoing Clinical Trials on Tradipitant

  • Safety Study of Tradipitant for Patients with Idiopathic or Diabetic Gastroparesis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany

Glossary

  • Gastroparesis: A digestive disorder in which the stomach takes too long to empty its contents. It can cause nausea, vomiting, early satiety, and abdominal pain.
  • Neurokinin-1 (NK-1) receptor antagonist: A type of drug that blocks the action of substance P, a neurotransmitter involved in various bodily functions, including nausea and vomiting.
  • Functional Dyspepsia: A chronic condition of pain or discomfort in the upper abdomen, often accompanied by bloating, early satiety, or nausea, without an identifiable cause.
  • Motion Sickness: A condition characterized by nausea, vomiting, and dizziness, typically caused by movement in a vehicle or other motion-inducing environments.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being studied.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Efficacy: The ability of a drug or treatment to produce the desired effect or outcome in controlled clinical trials.
  • Gastric Accommodation: The ability of the stomach to relax and expand to accommodate food and liquid during and after a meal.
  • Gastric Emptying: The process by which food leaves the stomach and enters the small intestine.
  • Single Photon Emission Computed Tomography (SPECT): An imaging technique used to measure various aspects of gastric function, including gastric volume and accommodation.
  • GLP-1R Agonist: A class of medications that mimic the effects of the hormone GLP-1, often used for treating diabetes and obesity.
  • Scintigraphy: An imaging technique that uses small amounts of radioactive material to diagnose or treat various conditions, including measuring gastric emptying.

References

  1. https://clinicaltrials.gov/study/NCT04474990
  2. https://clinicaltrials.gov/study/NCT06138613
  3. https://clinicaltrials.gov/study/NCT05903924
  4. https://clinicaltrials.gov/study/NCT04028492
  5. https://clinicaltrials.gov/study/NCT05653310
  6. https://clinicaltrials.gov/study/NCT04326426
  7. https://clinicaltrials.gov/study/NCT02621385